Bobak R. Azamian Sells 8,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSGet Rating) CEO Bobak R. Azamian sold 8,000 shares of the business’s stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $14.56, for a total transaction of $116,480.00. Following the transaction, the chief executive officer now owns 1,116,613 shares in the company, valued at $16,257,885.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock opened at $14.93 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.40 and a quick ratio of 16.40. The firm’s 50-day moving average is $15.51 and its two-hundred day moving average is $16.05. Tarsus Pharmaceuticals, Inc. has a 12 month low of $10.80 and a 12 month high of $21.47. The company has a market capitalization of $398.21 million, a PE ratio of -5.37 and a beta of 0.67.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last issued its earnings results on Wednesday, November 9th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.14. Tarsus Pharmaceuticals had a negative net margin of 324.99% and a negative return on equity of 34.24%. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Oppenheimer reduced their target price on shares of Tarsus Pharmaceuticals from $66.00 to $43.00 in a research note on Thursday, November 10th.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in TARS. Dimensional Fund Advisors LP raised its stake in shares of Tarsus Pharmaceuticals by 221.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock valued at $485,000 after acquiring an additional 19,865 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Tarsus Pharmaceuticals by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after acquiring an additional 1,402 shares during the period. UBS Group AG raised its stake in shares of Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after acquiring an additional 1,142 shares during the period. Invesco Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 17.1% in the 1st quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock valued at $471,000 after acquiring an additional 4,078 shares during the period. Finally, State Street Corp raised its stake in shares of Tarsus Pharmaceuticals by 2.4% in the 1st quarter. State Street Corp now owns 132,883 shares of the company’s stock valued at $2,235,000 after acquiring an additional 3,141 shares during the period. 76.82% of the stock is owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

See Also

Insider Buying and Selling by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.